DiaMedica Therapeutics (DMAC) Projected to Announce Earnings on Tuesday

by · The Cerbat Gem

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) is expected to post its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.19) per share and revenue of $13.50 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:00 AM ET.

DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Stock Performance

Shares of DiaMedica Therapeutics stock traded up $0.01 during trading on Tuesday, hitting $6.53. The company’s stock had a trading volume of 40,643 shares, compared to its average volume of 206,175. The company has a fifty day simple moving average of $6.55 and a two-hundred day simple moving average of $6.99. The company has a market capitalization of $351.57 million, a PE ratio of -9.19 and a beta of 1.01. DiaMedica Therapeutics has a 52 week low of $4.31 and a 52 week high of $10.42.

Analyst Ratings Changes

DMAC has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Check Out Our Latest Stock Analysis on DiaMedica Therapeutics

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in shares of DiaMedica Therapeutics during the third quarter valued at approximately $8,157,000. Geode Capital Management LLC boosted its stake in DiaMedica Therapeutics by 99.6% during the 2nd quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after purchasing an additional 314,407 shares during the last quarter. Royal Bank of Canada increased its holdings in shares of DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after purchasing an additional 154,701 shares in the last quarter. State Street Corp raised its stake in shares of DiaMedica Therapeutics by 31.7% in the fourth quarter. State Street Corp now owns 627,771 shares of the company’s stock worth $4,997,000 after purchasing an additional 151,188 shares during the last quarter. Finally, Osaic Holdings Inc. raised its stake in shares of DiaMedica Therapeutics by 374.7% in the second quarter. Osaic Holdings Inc. now owns 144,290 shares of the company’s stock worth $563,000 after purchasing an additional 113,893 shares during the last quarter. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Company Profile

(Get Free Report)

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

Featured Stories